During the past decade, Mount Sinai Tisch Cancer Institute conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mount Sinai Tisch Cancer Institute" #1 collaborator was "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Mount Sinai Tisch Cancer Institute" are "Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia" (1 trials) and "Urothelial Carcinoma" (1 trials). Many other conditions were trialed in "Mount Sinai Tisch Cancer Institute" in a lesser frequency.

Most popular intervention types in "Mount Sinai Tisch Cancer Institute" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (1 trials), "Fludarabine" (1 trials), "brexucabtagene autoleucel" (1 trials), "disitamab vedotin" (1 trials) and "pembrolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mount Sinai Tisch Cancer Institute" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Mount Sinai Tisch Cancer Institute". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Mount Sinai Tisch Cancer Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mount Sinai Tisch Cancer Institute, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".